# A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma

Source: https://onco.cc/trials/nct05043922/  
OnCo record `nct05043922` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of CYH33 in ovarian cancer, run by Haihe Biopharma Co., Ltd., active and no longer recruiting.

## Summary

A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma is a phase 2 interventional study registered as NCT05043922 by Haihe Biopharma Co., Ltd., with 93 participants enrolled, started 2021-10-11 and due to reach its primary completion in 2024-07-31. Interventions recorded: CYH33.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05043922
- Phase: 2
- Setting: A Phase II, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of CYH33, a Selective PI3Kα Inhibitor in Patients With Recurrent/Persistent Ovary, Fallopian Tube or Primary Peritoneal Clear Cell Carcinoma
- Sponsor: Haihe Biopharma Co., Ltd.
- Enrolled: 93

## Sources

- ClinicalTrials.gov NCT05043922: https://clinicaltrials.gov/study/NCT05043922

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- companies: [Haihe Biopharma](https://onco.cc/companies/haihe-biopharma/)
- drugs: [CYH33](https://onco.cc/drugs/cyh33/)

---
JSON: https://onco.cc/api/v1/entities/nct05043922.json